ASO VISUAL ABSTRACT

ASO Visual Abstract: Perioperative Chemotherapy is Associated with Superior Overall Survival in Patients with Synchronous Colorectal Liver Metastases

Joy Sarkar, MD¹, Kristopher Attwood, PhD², and Roderich E. Schwarz, MD¹

¹Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY; ²Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY

In a retrospective study of 43,039 patients with synchronous liver-only metastases from colorectal cancer (https://doi.org/10.1245/s10434-023-14302-9), receipt of perioperative chemotherapy with resection correlated with superior

overall survival (median 44.7 months). Additionally, superior overall survival was more closely linked to resection of the metastatic site than to resection of the primary tumor.

Perioperative Chemotherapy Is Associated with Superior Overall Survival in **Patients with Synchronous Colorectal Liver Metastases Treatment Sequences - Metastasectomy** Sequence of Perioperative chemotherapy + liver localized and resection was associated with best systemic treatment median OS of 54.8 months vs 37.7 for colorectal liver 0.6 months for liver resection + metastases (CRLM) postoperative chemotherapy 0.4 remains debated **National Cancer Database analysis:** 43,039 patients with liver-only CRLM All patients with resectable CRLM 8,678 patients deserve formal multimodality underwent liver evaluation prior to finalizing treatment resection nlan Multivariate analysis Sarkar et al. Ann Surg Oncol. URGICAL Visual Abstract for @AnnSurgOncol

© Society of Surgical Oncology 2023 Published online: 31 October 2023

J. Sarkar, MD e-mail: joy.sarkar07@outlook.com **DISCLOSURE** The authors have no potential conflicts of interest to disclose.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.